Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Campylobacter jejuni Conjugate Vaccine
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
CJCV2 is an experimental conjugate vaccine developed to prevent infection by Campylobacter jejuni, a leading cause of bacterial gastroenteritis and diarrhea worldwide. The vaccine is designed to stimulate the immune system to produce protective antibodies against C. jejuni, potentially reducing the risk of severe illness, especially in vulnerable populations such as young children and immunocompromised individuals. In clinical trials, CJCV2 has been evaluated both alone and in combination with the Army Liposome Formulation containing QS-21 (ALFQ) adjuvant, which is intended to enhance immunogenicity. The primary goal of ongoing studies is to assess safety and immune response following intramuscular administration[2][3][4].
- Other names
- Campylobacter jejuni Conjugate Vaccine
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on Campylobacter jejuni Conjugate Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Campylobacter jejuni Conjugate Vaccine.